Sage Journals: Discover world-class research

Abstract

Background:

There are questions about the risk-benefit balance of longer-term antipsychotic medication treatment following first episode psychosis, especially in relation to relapse because of dopamine supersensitivity following treatment cessation.

Aim:

The purpose of this study was to determine whether hospitalization rates in first episode psychosis patients are associated with length of initial oral antipsychotic medication exposure.

Methods:

We examined psychiatric hospitalization rates in patients experiencing first episode of psychosis from the total population of Sweden between 1 January 2007–31 December 2016 (n=7043). We categorised patients by the length of first antipsychotic treatment (<6 months, 6 months to <1 year, 1 year to <2 years, 2 years to <5 years and ⩾5 years).

Results:

Compared to those treated for <6 months, individuals receiving oral antipsychotic medications for ⩾5 years had less than half the cumulative incidence of hospitalization at all times between 1–4 years after treatment cessation.

Conclusion:

We found no evidence that hospitalization rates increased with increasing baseline antipsychotic exposure.

Keywords

Relapse hospitalization first episode psychosis antipsychotic medication

Get full access to this article

View all access options for this article.

References

Austin

Fine

(2017) Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med 36: 4391–4400.

Correll

Rubio

Kane

(2018) What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17: 149–160.

Fine

Gray

(1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: 496–509.

Goff

Falkai

Fleischhacker

et al . (2017) The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry 174: 840–849.

Leucht

(2018) Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed? World Psychiatry 17: 166–167.

Murray

Quattrone

Natesan

et al . (2016) Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 209: 361–365.

Tiihonen

Tanskanen

Taipale

(2018) 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 175: 765–773.

Zohar

Stahl

Moller

et al . (2015) A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol 25: 2318–2325.